EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic, Germany, Italy and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
Clinical Pharmacy Services
E Paradela, M Rodríguez, A Romero, MD Alvarado
To treat a 72-year-old patient admitted to the ICU who developed GMG as an adverse effect to his first cycle of pembrolizumab (an immune checkpoint inhibitor drug).
This case report describes the use of efgartigimod, a high economic impact drug indicated in adult patients with generalized myasthenia gravis (GMG) who are antibody-positive against acetylcholine receptors (AChR), not controlled with pyridostigmine, corticosteroids and at least two conventional immunosuppressive therapies.
In June 2024, the patient was diagnosed with a melanoma recurrence and started an adjuvant treatment with pembrolizumab. 18 days after his first cycle, the patient went to the emergency room with characteristic GMG symptoms such as asthenia, myalgia, proximal limb weakness and ptosis in both eyes.
The treatment consisted of methylprednisolone (2 mg/kg), immunosuppressants (tacrolimus), high-dose pyridostigmine (90 mg/4 h), immunoglobulins (2 g/kg) and 7 plasmapheresis sessions. Tacrolimus was included as immunosuppressive therapy and cyclosporine was intended to be started, but both were discontinued due to the risk of worsening the bicytopenia. It was then decided to perform an antibody study in order to guide the treatment. The positive result of the anti-AChR antibodies and the lack of control of the pathology after conventional treatment, suggested starting a treatment with efgartigimod 800 mg/week for 4 weeks.
After four efgartigimod cycles, there was a progressive improvement in neurological weakness, with persistent oculomotor impairment and palpebral ptosis. Almost two months after the efgartigimod treatment, an excellent progressive evolution has been observed and discharge is expected in one week. Nowadays, the patient continues with high doses of pyridostigmine, prednisone in a descending regimen and follow-up by dysphagia and speech therapy units.
Myasthenia gravis is an immune-related adverse effect caused by checkpoint inhibitors, such as pembrolizumab, whose prevalence is growing with the increasing use of these drugs. In cases of persistent MG, efgartigimod is considered an effective option as an add-on treatment that provides symptom improvement in clinical practice.
